Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development
December 12 2013 - 8:30AM
Business Wire
Company Strengthens Clinical Team as it Nears
Phase II Trials in AMD and SMD
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in
the field of regenerative medicine, today announced the appointment
of Eddy Anglade, M.D., to the newly created position of Executive
Vice President of Clinical Development. Dr. Anglade is an
ophthalmologist and an experienced pharmaceutical executive with
more than 16 years of experience overseeing all elements of
clinical trials and regulatory affairs.
“We created the new position, EVP of Clinical Development, as we
prepare for our transition to Phase II of our AMD and SMD clinical
trials. We are thrilled to welcome such an experienced and
accomplished executive to our team at this critical point in the
Company’s evolution,” said Gary Rabin, CEO of ACT. “Dr. Anglade has
extensive experience in the development of therapeutics for
treating diseases of the eye. He will make an excellent addition to
the world-class management team at ACT as the Company continues to
work with its clinical development partners at many of the leading
academic and scientific institutions in the world.”
Dr. Anglade joins ACT after co-founding Lux Pharmaceuticals and
serving as its Chief Medical Officer, where he guided the
development of orphan designated and fast-track products as well as
early phase development of a novel therapeutic agent for dry eye
disease. His responsibilities included recruitment and development
of the clinical operations, program management, and medical writing
teams, as well as serving as the safety officer responsible for
review of all studies. Previously he was Vice President of Clinical
Development at Enzon Pharmaceuticals, where he oversaw all clinical
development activities and was a member of the research and
development leadership team, and designed the industry’s first
multi-center, randomized, placebo-controlled and blinded study of
an agent for the prevention of rejection in lung transplantation.
He served as a medical director for Hoffman-La Roche Inc. where he
developed and implemented clinical strategies for their CellCept®
and Cytovene® drugs and served as the medical monitor for Zenapax®
in cardiac transplantation. Dr. Anglade holds an M.D. from Yale
University. He completed his residency in ophthalmology at
Massachusetts Eye and Ear Infirmary/Harvard Medical School, and
received additional training in ocular immunology at the National
Eye Institute/National Institutes of Health. He is an extensively
published author in eye disease and immunology.
“ACT is a great opportunity. The data from the Phase I AMD and
SMD trials are very encouraging. I am excited to join the team and
look forward to helping in guiding the clinical and regulatory
strategy as the Company progresses through its clinical trials,
ultimately toward market approval,” commented Dr. Anglade. “Macular
degenerative diseases represent large and important unmet medical
needs. I look forward to applying my experience in this field to
move ACT’s novel therapies to the tens of millions of patients
suffering from these diseases.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., a biotechnology company, engages
in the development and commercialization of human embryonic and
adult stem cell technology in the field of regenerative medicine.
The Company is conducting several clinical trials for treating
macular degeneration, and has a preclinical development pipeline
focused on products for eye diseases, autoimmune and inflammatory
diseases, and wound healing. Its intellectual property portfolio
includes pluripotent stem cell platforms comprising embryonic stem
cell and induced pluripotent stem cell (iPSC) platforms; and other
cell therapy research programs. The Company is headquartered in
Marlborough, Massachusetts. For more information,
http://www.advancedcell.com or connect with the Company on
Facebook, Twitter, LinkedIn, Google+, and YouTube.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities
for the Company and any other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history,
need for future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the Company’s periodic reports, including our report on
Form 10-K for the year ended December 31, 2012 and our report on
Form 10-Q for the three months ended September 30, 2013.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the Company’s management at the time they are made,
and the Company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the Company’s management at the time they are made, and the Company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the
Company’s clinical trials or other development programs will be
successful.
Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo
PartnersDavid Schull, 858-717-2310